Please enable JavaScript to continue using this application.

Compare $AVTX vs $PRME | Chartloom

Compare

$AVTX vs $PRME

Avalo Therapeutics Inc · Prime Medicine Inc

AVTX

Avalo Therapeutics Inc

PRME

Prime Medicine Inc

Compare $AVTX vs $PRME

Comparing Avalo Therapeutics Inc and Prime Medicine Inc

AVTXAvalo Therapeutics Inc

PRMEPrime Medicine Inc

AVTXAvalo Therapeutics Inc

Market cap

$722M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-86.6%

YTD performance

-19.8%

52W performance

-4.0%

FCF yield

-9.5%

PRMEPrime Medicine Inc

Market cap

$721M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

126.79x

Rev growth (TTM)

-17.9%

YTD performance

13.0%

52W performance

-38.1%

FCF yield

-21.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AVTX

PRME

Detailed metrics comparison

AVTX

Avalo Therapeutics Inc

PRME

Prime Medicine Inc

Market Cap

AVTX$722M

PRME$721M

Enterprise Value

AVTX$639M

PRME$673M

Price

AVTX$13.65

PRME$3.99

P/E Ratio

AVTXN/A

PRMEN/A

P/S Ratio

AVTX12,238.73x

PRME176.94x

EV/Sales

AVTX10,825.47x

PRME165.29x

EV/EBITDA

AVTX0.00x

PRME0.00x

P/B Ratio

AVTX1.79x

PRME13.58x

P/FCF Ratio

AVTXN/A

PRMEN/A

EV/FCF

AVTX-9.35x

PRME-4.29x

PEG Ratio

AVTXN/A

PRMEN/A

Forward P/E (NTM)

AVTXN/A

PRMEN/A

Forward P/S (NTM)

AVTXN/A

PRME126.79x

Revenue (TTM)

AVTX$59K

PRME$4M

Revenue Growth (YoY)

AVTX-86.6%

PRME-17.9%

Forward Rev Growth

AVTX1345.1%

PRME22.7%

Gross Margin (TTM)

AVTX242.2%

PRME0.0%

Operating Margin (TTM)

AVTX0.0%

PRME0.0%

EBITDA Margin (TTM)

AVTX-154659.3%

PRME-4643.3%

Net Margin (TTM)

AVTX-170055.9%

PRME-4613.1%

FCF Margin (TTM)

AVTX-115745.8%

PRME-3850.9%

Net Income (TTM)

AVTX$-100M

PRME$-188M

FCF (TTM)

AVTX$-68M

PRME$-157M

EPS (TTM)

AVTX-$2.30

PRME-$1.06

ROE (TTM)

AVTX-5803.0%

PRME-18827.0%

ROA (TTM)

AVTX-4822.0%

PRME-5911.0%

ROIC (TTM)

AVTX-5729.0%

PRME-18827.0%

Cash

AVTX$85M

PRME$47M

Debt

AVTX$2M

PRME$0

Net Cash/Debt

AVTX$83M

PRME$47M

Current Ratio (TTM)

AVTX19.31x

PRME3.05x

Quick Ratio (TTM)

AVTX18.95x

PRME3.01x

Debt/Equity (TTM)

AVTX0.00x

PRME0.00x

Debt/Assets (TTM)

AVTX0.0%

PRME0.0%

Interest Coverage (TTM)

AVTXN/A

PRMEN/A

Net Debt/EBITDA (TTM)

AVTX0.00x

PRME0.00x

Beta

AVTX0.62

PRME2.35

52W Performance

AVTX-4.0%

PRME-38.1%

YTD Performance

AVTX-19.8%

PRME13.0%

% from 52W High

AVTX-43.8%

PRME-40.0%

% from 52W Low

AVTX9.1%

PRME49.4%

Asset Turnover (TTM)

AVTX0.00x

PRME0.01x

FCF Yield (TTM)

AVTX-9.5%

PRME-21.8%

Earnings Yield (TTM)

AVTX-13.9%

PRME-26.1%

Dividend Yield (TTM)

AVTXN/A

PRMEN/A

Rule of 40

AVTX-115,832.4

PRME-3,868.8

EV/GP/RG

AVTX1.31

PRMEN/A

Ticker research

View AVTX research View PRME research

Metric	AVTX Avalo Therapeutics Inc	PRME Prime Medicine Inc
Market & Valuation
Market Cap	$722M	$721M
Enterprise Value	$639M	$673M
Price	$13.65	$3.99
P/E Ratio	N/A	N/A
P/S Ratio	12,238.73x	176.94x
EV/Sales	10,825.47x	165.29x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.79x	13.58x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.35x	-4.29x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	126.79x
Revenue & Growth
Revenue (TTM)	$59K	$4M
Revenue Growth (YoY)	-86.6%	-17.9%
Forward Rev Growth	1345.1%	22.7%
Profitability
Gross Margin (TTM)	242.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-154659.3%	-4643.3%
Net Margin (TTM)	-170055.9%	-4613.1%
FCF Margin (TTM)	-115745.8%	-3850.9%
Net Income (TTM)	$-100M	$-188M
FCF (TTM)	$-68M	$-157M
EPS (TTM)	-$2.30	-$1.06
ROE (TTM)	-5803.0%	-18827.0%
ROA (TTM)	-4822.0%	-5911.0%
ROIC (TTM)	-5729.0%	-18827.0%
Financial Health
Cash	$85M	$47M
Debt	$2M	$0
Net Cash/Debt	$83M	$47M
Current Ratio (TTM)	19.31x	3.05x
Quick Ratio (TTM)	18.95x	3.01x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	2.35
52W Performance	-4.0%	-38.1%
YTD Performance	-19.8%	13.0%
% from 52W High	-43.8%	-40.0%
% from 52W Low	9.1%	49.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-9.5%	-21.8%
Earnings Yield (TTM)	-13.9%	-26.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-115,832.4	-3,868.8
EV/GP/RG	1.31	N/A
Ticker research	View AVTX research	View PRME research

Valuation

P/S Ratio

PRME

176.94x

AVTX

12,238.73x

EV/FCF

AVTX

-9.35x

PRME

-4.29x

Growth & revenue

Revenue Growth TTM

PRME

-17.9%

AVTX

-86.6%

Forward Revenue Growth

AVTX

1345.1%

PRME

22.7%

Profitability & performance

Gross Margin

AVTX

242.2%

PRME

0.0%

ROE

AVTX

-5803.0%

PRME

-18827.0%

FCF Yield %

AVTX

-9.5%

PRME

-21.8%

52-Week Performance

AVTX

-4.0%

PRME

-38.1%

Detailed metrics comparison

AVTX

Avalo Therapeutics Inc

PRME

Prime Medicine Inc

Market Cap

AVTX$722M

PRME$721M

Enterprise Value

AVTX$639M

PRME$673M

Price

AVTX$13.65

PRME$3.99

P/E Ratio

AVTXN/A

PRMEN/A

P/S Ratio

AVTX12,238.73x

PRME176.94x

EV/Sales

AVTX10,825.47x

PRME165.29x

EV/EBITDA

AVTX0.00x

PRME0.00x

P/B Ratio

AVTX1.79x

PRME13.58x

P/FCF Ratio

AVTXN/A

PRMEN/A

EV/FCF

AVTX-9.35x

PRME-4.29x

PEG Ratio

AVTXN/A

PRMEN/A

Forward P/E (NTM)

AVTXN/A

PRMEN/A

Forward P/S (NTM)

AVTXN/A

PRME126.79x

Revenue (TTM)

AVTX$59K

PRME$4M

Revenue Growth (YoY)

AVTX-86.6%

PRME-17.9%

Forward Rev Growth

AVTX1345.1%

PRME22.7%

Gross Margin (TTM)

AVTX242.2%

PRME0.0%

Operating Margin (TTM)

AVTX0.0%

PRME0.0%

EBITDA Margin (TTM)

AVTX-154659.3%

PRME-4643.3%

Net Margin (TTM)

AVTX-170055.9%

PRME-4613.1%

FCF Margin (TTM)

AVTX-115745.8%

PRME-3850.9%

Net Income (TTM)

AVTX$-100M

PRME$-188M

FCF (TTM)

AVTX$-68M

PRME$-157M

EPS (TTM)

AVTX-$2.30

PRME-$1.06

ROE (TTM)

AVTX-5803.0%

PRME-18827.0%

ROA (TTM)

AVTX-4822.0%

PRME-5911.0%

ROIC (TTM)

AVTX-5729.0%

PRME-18827.0%

Cash

AVTX$85M

PRME$47M

Debt

AVTX$2M

PRME$0

Net Cash/Debt

AVTX$83M

PRME$47M

Current Ratio (TTM)

AVTX19.31x

PRME3.05x

Quick Ratio (TTM)

AVTX18.95x

PRME3.01x

Debt/Equity (TTM)

AVTX0.00x

PRME0.00x

Debt/Assets (TTM)

AVTX0.0%

PRME0.0%

Interest Coverage (TTM)

AVTXN/A

PRMEN/A

Net Debt/EBITDA (TTM)

AVTX0.00x

PRME0.00x

Beta

AVTX0.62

PRME2.35

52W Performance

AVTX-4.0%

PRME-38.1%

YTD Performance

AVTX-19.8%

PRME13.0%

% from 52W High

AVTX-43.8%

PRME-40.0%

% from 52W Low

AVTX9.1%

PRME49.4%

Asset Turnover (TTM)

AVTX0.00x

PRME0.01x

FCF Yield (TTM)

AVTX-9.5%

PRME-21.8%

Earnings Yield (TTM)

AVTX-13.9%

PRME-26.1%

Dividend Yield (TTM)

AVTXN/A

PRMEN/A

Rule of 40

AVTX-115,832.4

PRME-3,868.8

EV/GP/RG

AVTX1.31

PRMEN/A

Ticker research

View AVTX research View PRME research

Metric	AVTX Avalo Therapeutics Inc	PRME Prime Medicine Inc
Market & Valuation
Market Cap	$722M	$721M
Enterprise Value	$639M	$673M
Price	$13.65	$3.99
P/E Ratio	N/A	N/A
P/S Ratio	12,238.73x	176.94x
EV/Sales	10,825.47x	165.29x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.79x	13.58x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.35x	-4.29x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	126.79x
Revenue & Growth
Revenue (TTM)	$59K	$4M
Revenue Growth (YoY)	-86.6%	-17.9%
Forward Rev Growth	1345.1%	22.7%
Profitability
Gross Margin (TTM)	242.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-154659.3%	-4643.3%
Net Margin (TTM)	-170055.9%	-4613.1%
FCF Margin (TTM)	-115745.8%	-3850.9%
Net Income (TTM)	$-100M	$-188M
FCF (TTM)	$-68M	$-157M
EPS (TTM)	-$2.30	-$1.06
ROE (TTM)	-5803.0%	-18827.0%
ROA (TTM)	-4822.0%	-5911.0%
ROIC (TTM)	-5729.0%	-18827.0%
Financial Health
Cash	$85M	$47M
Debt	$2M	$0
Net Cash/Debt	$83M	$47M
Current Ratio (TTM)	19.31x	3.05x
Quick Ratio (TTM)	18.95x	3.01x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	2.35
52W Performance	-4.0%	-38.1%
YTD Performance	-19.8%	13.0%
% from 52W High	-43.8%	-40.0%
% from 52W Low	9.1%	49.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-9.5%	-21.8%
Earnings Yield (TTM)	-13.9%	-26.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-115,832.4	-3,868.8
EV/GP/RG	1.31	N/A
Ticker research	View AVTX research	View PRME research